Abstract

The COVID-19 pandemic has led to over 2.26 million deaths for almost 104 million confirmed cases worldwide, as of 4 February 2021 (WHO). Risk factors include pre-existing conditions such as cancer, cardiovascular disease, diabetes, and obesity. Although several vaccines have been deployed, there are few alternative anti-viral treatments available in the case of reduced or non-existent vaccine protection. Adopting a long-term holistic approach to cope with the COVID-19 pandemic appears critical with the emergence of novel and more infectious SARS-CoV-2 variants. Our objective was to identify comorbidity-associated single nucleotide polymorphisms (SNPs), potentially conferring increased susceptibility to SARS-CoV-2 infection using a computational meta-analysis approach. SNP datasets were downloaded from a publicly available genome-wide association studies (GWAS) catalog for 141 of 258 candidate COVID-19 comorbidities. Gene-level SNP analysis was performed to identify significant pathways by using the program MAGMA. An SNP annotation program was used to analyze MAGMA-identified genes. Differential gene expression was determined for significant genes across 30 general tissue types using the Functional and Annotation Mapping of GWAS online tool GENE2FUNC. COVID-19 comorbidities (n = 22) from six disease categories were found to have significant associated pathways, validated by Q–Q plots (p < 0.05). Protein–protein interactions of significant (p < 0.05) differentially expressed genes were visualized with the STRING program. Gene interaction networks were found to be relevant to SARS and influenza pathogenesis. In conclusion, we were able to identify the pathways potentially affected by or affecting SARS-CoV-2 infection in underlying medical conditions likely to confer susceptibility and/or the severity of COVID-19. Our findings have implications in future COVID-19 experimental research and treatment development.

Highlights

  • The aim of this study was to complete an single nucleotide polymorphisms (SNPs) meta-analysis to identify genes associated with comorbidities/underlying medical conditions, potentially conferring increased susceptibility to severe acute respiratory syndrome (SARS)-CoV-2 infection or leading to the manifestation of severe viral symptoms

  • This list of 258 subcategories represented comorbidities/underlying medical conditions possibly associated with increased SARS-CoV-2 infectivity or disease severity

  • Due to the lack of published work for some subcategories, if the Centers for Disease Control and Prevention (CDC) stated that individuals with underlying heart conditions were at an increased risk for COVID-19, other cardiovascular conditions were included as subcategories

Read more

Summary

Introduction

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. The COVID-19 pandemic’s first identified cases can be traced back to Wuhan, China, in December of 2019 [1]. As of 4 February, 2021 (WHO), there have been over 103.9 million confirmed COVID-19 cases affecting over 200 countries [2]. This staggering number of cases includes more than 2.26 million deaths, with the U.S representing roughly one fourth of cases and deaths. A study at Stanford University estimated the infection fatality rate to be between 1.54 and 1.63%, which is significantly higher than the reported average mortality rate of 0.1% for influenza [3]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call